Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QR12000 tablets in primary hypertension with type 2 diabetes mellitus
CTR20253529Phase 3Active
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd.
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of QR12000 in essential hypertension, type 2 diabetes mellitus (T2DM), sponsored by Wuhan Createrna Science and Technology Co., Ltd.. Started Oct 2025; status: active.
02
Drugs
QR12000
03
Conditions
essential hypertensiontype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20253529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253529.